Amedisys (AMED) Stock Price, News & Analysis

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 7 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AMED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMED, but not buy additional shares or sell existing shares.
View AMED analyst ratings or view top-rated stocks.

8 Wall Street research analysts have issued 1 year price objectives for Amedisys' shares. Their AMED share price targets range from $81.00 to $101.00. On average, they anticipate the company's share price to reach $97.50 in the next year. This suggests a possible upside of 7.2% from the stock's current price.
View analysts price targets for AMED or view top-rated stocks among Wall Street analysts.

Amedisys' stock was trading at $95.06 on January 1st, 2024. Since then, AMED shares have decreased by 4.3% and is now trading at $90.96.
View the best growth stocks for 2024 here.

Amedisys saw a drop in short interest during the month of March. As of March 31st, there was short interest totaling 2,490,000 shares, a drop of 20.2% from the March 15th total of 3,120,000 shares. Based on an average trading volume of 291,300 shares, the short-interest ratio is currently 8.5 days. Currently, 7.8% of the company's shares are short sold.
View Amedisys' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our AMED earnings forecast.

Amedisys, Inc. (NASDAQ:AMED) posted its earnings results on Wednesday, February, 21st. The health services provider reported $0.94 earnings per share for the quarter, missing the consensus estimate of $1.04 by $0.10. The health services provider had revenue of $570.79 million for the quarter, compared to the consensus estimate of $566.85 million. Amedisys had a negative net margin of 0.44% and a positive trailing twelve-month return on equity of 12.76%. The business's revenue for the quarter was up 1.6% on a year-over-year basis. During the same period in the previous year, the business posted $1.16 EPS.

ETFs with the largest weight of Amedisys (NASDAQ:AMED) stock in their portfolio include First Trust Merger Arbitrage ETF (MARB), IQ Merger Arbitrage ETF (MNA), SPDR S&P Health Care Services ETF (XHS), SRH U.S. Quality ETF (SRHQ), AltShares Event-Driven ET (EVNT), AltShares Merger Arbitrage ETF (ARB) and Fundamentals First ETF (KNOW).iShares U.S. Healthcare Providers ETF (IHF).

478 employees have rated Amedisys Chief Executive Officer Paul B. Kusserow on Glassdoor.com. Paul B. Kusserow has an approval rating of 79% among the company's employees. 60.0% of employees surveyed would recommend working at Amedisys to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Adobe (ADBE), Intel (INTC), QUALCOMM (QCOM), Broadcom (AVGO), Cisco Systems (CSCO) and Home Depot (HD).

Amedisys' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Bridge City Capital LLC (0.09%) and Banque Cantonale Vaudoise (0.00%). Insiders that own company stock include Bruce D Perkins, Christopher Gerard, David L Kemmerly, Denise M Bohnert, Michael Paul North, Richard A Lechleiter and Scott G Ginn.
View institutional ownership trends.

Shares of AMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.